Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 4, 2021, Pages

  O'Shea, Orlagh ^a   Stovold, Elizabeth ^b   Cates, Christopher J ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BUDESONIDE PLUS FORMOTEROL; BUDESONIDE PLUS SALMETEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; SALMETEROL; ANTIASTHMATIC AGENT; BECLOMETASONE; BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE; FORMOTEROL FUMARATE; GLUCOCORTICOID; MOMETASONE FUROATE; SALMETEROL XINAFOATE;

ALL CAUSE MORTALITY; ASTHMA; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MAINTENANCE THERAPY; MORTALITY RISK; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SELECTION; PUBLICATION BIAS; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; ADVERSE EVENT; CHILD; CHRONIC DISEASE; COMBINATION DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FLUTICASONE; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; MOMETASONE FUROATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALMETEROL XINAFOATE;

EID: 85104257977     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007694.pub3     Document Type: Review

References (181)

1. Aalbers R, Backer V, Kava TT, Welte T, Omenaas ER, Bergqvist PBF, et al. Adjustable dosing with budesonide/formoterol reduces the rate of asthma exacerbations compared with fixed dosing salmeterol/fluticasone. European Respiratory Journal 2003;41:2-20. x-wiley/crsRef/3301279
2. Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandstrom T, Jorup C, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research and Opinion 2004;20(2):225-40. x-wiley/crsRef/3301280
3. Aalbers R, Harris A, Naya I. Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment. European Respiratory Journal 2005;26(Suppl 49):50s. x-wiley/crsRef/3301281
4. Aalbers R, Welte T, Jorup C. Adjustable maintenance dosing (AMD) with budesonide /formoterol (B/F) meets guideline-defined management goals more effectively than fixed dosing (FD) with B/F or salmeterol/fluticasone (S/FL). European Respiratory Journal 2004;24(Suppl 48):311s. x-wiley/crsRef/3301282
5. Aalbers R. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol fluticasone propionate in asthma patients aged [greater-than or equal to]16 years: post hoc analysis of a randomised, double-blind open-label extension, parallel-group study. Clinical Drug Investigation 2010;30(7):439-51. x-wiley/crsRef/3301283
6. AstraZeneca SD-039-0686. A randomized, double-dummy, double-blind/open, parallel-group, phase-III, multicentre, 7-month study to assess the efficacy and safety of Symbicort® Turbuhaler® (budesonide/formoterol; 160/4.5 mcg delivered dose) given either as standard therapy (2 inhalations bid) or with an adjustable dosing regimen (1, 2 or 4 inhalations bid) versus Seretide™ Diskus™ (salmeterol/fluticasone; 50/250 mcg metered dose) given as standard therapy (1 inhalation bid) in adult and adolescent asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1004 (first received 1 October 2001). x-wiley/crsRef/3301284
7. Welte T, Aalbers R, Naya I. Budesonide/formoterol adjustable maintenance dosing (B/F AMD) reduces the burden of asthma more effectively than fixed dosing (FD) with B/F or salmeterol/fluticasone (S/FL) [Abstract]. European Respiratory Journal 2004;24(Suppl 48):508s. x-wiley/crsRef/3301285
8. Akamatsu T, Shirai T, Kato M, Yasui H, Hashimoto D, Fujisawa T, et al. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma. Pulmonary Pharmacology and Therapeutics 2014;27(1):52-6. x-wiley/crsRef/15978827
9. UMIN000009619. Treatment effect of switching from salmeterol/fluticasone to formoterol/budesonide combinations in patients with asthma. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011286 (first received 25 December 2012). x-wiley/crsRef/15978828
10. Bernstein D, Murphy K, Nolte H. Efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma: noninferiority and onset-of-action findings. Breast 2019;44:S62. x-wiley/crsRef/15978830
11. Bernstein D, Murphy K, Nolte H. Efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma: noninferiority and onset-of-action findings. World Allergy Organization Journal 2012;5:S79. x-wiley/crsRef/15978831
12. Bernstein DI, Hebert J, Cheema A, Murphy KR, Cherrez-Ojeda I, Matiz-Bueno CE, et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy, Asthma, and Clinical Immunology 2011;7(1):21. x-wiley/crsRef/15978832
13. Bernstein DI, Murphy KR, Nolte H. Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma. Allergy, Asthma, and Clinical Immunology 2010;6:33. x-wiley/crsRef/15978833
14. EUCTR-004169-33-SK. A 52-week efficacy and safety non-inferiority study of fluticasone propionate/salmeterol 250/50 mcg bid delivered by dry powder inhaler (DISKUS®) versus mometasone furoate/formoterol fumarate 200/10 mcg bid delivered by pressurized metered-dose inhaler in persistent asthmatics previously treated with medium doses of inhaled glucocorticosteroids. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-004169-33-SK (first received 10 April 2008). x-wiley/crsRef/15978834
15. NCT00424008. Study of inhaled glucocorticosteroids/long-acting bronchodilator drugs in subjects with asthma that have been taking inhaled glucocorticosteroids (study P04705AM1) [A 52-week efficacy and safety non-inferiority study of fluticasone propionate/salmeterol 250/50mcg bid delivered by dry powder inhaler (Diskus) versus mometasone furoate/formoterol fumarate 200/10mcg bid delivered by pressurized metered-dose inhaler in persistent asthmatics previously treated with medium doses of inhaled glucocorticosteroids]. clinicaltrials.gov/show/NCT00424008 (first received 18 January 2007). x-wiley/crsRef/15978835
16. Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A. Fluticasone/formoterol provides a more rapid bronchodilation than fluticasone/salmeterol over 12 weeks of treatment in patients with asthma. In: 6th IPCRG World Conference; 2012 April 25-28; Edinburgh. 2012:Abstract 269. x-wiley/crsRef/15978836
17. Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Advances in Therapy 2012;29(11):958-69. x-wiley/crsRef/15978837
18. Bodzenta-Lukaszyk A, Dymek A, Mansikka H. Fluticasone propionate/formoterol fumarate combination therapy has a more rapid onset of action than fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial. Thorax 2010;65(Suppl 4):P24. x-wiley/crsRef/15978838
19. Bodzenta-Lukaszyk A, Dymek A, Mansikka H. Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma. In: European Respiratory Society Annual Congress; 2010 September 18-22; Barcelona. 2010:[P1205]. x-wiley/crsRef/15978839
20. Bodzenta-Lukaszyk A, Dymek A, Mansikka H. Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial [Abstract]. Thorax 2010;65(Suppl 4):P177. x-wiley/crsRef/3301288
21. Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulmonary Medicine 2011;11:28. x-wiley/crsRef/15978840
22. Brusselle G, Aalbers R, McIver T, Grothe B, Bodzenta-Lukaszyk A. Onset of bronchodilation with fluticasone/formoterol versus fluticasone/salmeterol. European Respiratory Journal 2012;40:P2082. x-wiley/crsRef/15978841
23. Ambrose H, Lawrance R, Goldman M. Beta-adrenergic receptor gly16arg variation: effect on response to budesonide/formoterol or fluticasone propionate/salmeterol in asthma patients. Chest 2007;132(4):478a. x-wiley/crsRef/3301291
24. AstraZeneca D5896C00005. A two-stage randomized, open-label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair in subjects 12 years of age and older with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1583 (first received 1 November 2003). x-wiley/crsRef/3301292
25. Busse WW, Shah SR, Somerville L, Martin P, Goldman M. Comparison of asthma exacerbations and lung function with adjustable-dose budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI), fixed-dose BUD/FM pMDI, and fixed-dose fluticasone/salmeterol dry powder inhaler (FP/SM DPI). www.abstracts2view.com/ats07 (accessed prior to 11 October 2020):A191. x-wiley/crsRef/3301293
26. Busse WW, Shah SR, Somerville L, Parasuraman B, Martin P, Goldman M. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. Journal of Allergy and Clinical Immunology 2008;121(6):1407-14. x-wiley/crsRef/15978842
27. NCT00646594. Atlantis Symbicort [A two stage randomized, open-label, parallel group, phase III, multicenter, 7 month study to assess the efficacy & safety of SYMBICORT pMDI adminstered either as fixed or as an adjustable regimen versus a fixed regimen of Advair in subjects 12 yrs of age and older with asthma]. clinicaltrials.gov/show/NCT00646594 (first received 28 March 2008). x-wiley/crsRef/15978843
28. Shah SR, Busse WW, McElhattan J, O'Brien CD, Goldman M. Efficacy and tolerability of fixed-dose (FD) and adjustable-dose (AD) budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) and FD fluticasone propionate/salmeterol dry powder inhaler (FP/SAL DPI) within racial groups. Journal of Allergy and Clinical Immunology 2009;123(2 Suppl 1):S80. x-wiley/crsRef/3301295
29. Shah SR, Busse WW, Somerville L, Martin P, Goldman M. Asthma control with adjustable-and fixed-dose budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) and fixed-dose fluticasone/salmeterol dry powder inhaler (FP/SM DPI). In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #K4. x-wiley/crsRef/3301296
30. Somerville L, Busse WW, Shah SR, Martin P, Goldman M. Safety of adjustable-dose budesonide (BUD)/formoterol (FM) pressurized metered-dose inhaler (pMDI), fixed-dose (BUD/FM pMDI and fixed-dose fluticasone (FP)/salmeterol (SM) dry powder inhaler (DPI) in asthma patients. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:Poster #K3. x-wiley/crsRef/3301297
31. Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respiratory Medicine 2006;100(7):1152-62. x-wiley/crsRef/3301299
32. Dahl R, Chuchalin A, Lindberg A, Jones M, Aggarwal K, Gor D. EXCEL regular maintenance therapy with salmeterol/fluticasone propionate combination (SFC) reduces exacerbations more effectively than the formoterol/budesonide combination (FBC). European Respiratory Journal 2004;24(Suppl 48):309s. x-wiley/crsRef/3301300
33. Dahl R, Chuchalin A, Ringdal N, Gor D, Jones M. Salmeterol/fluticasone (SFC) reduces moderate/severe exacerbations more effectively than formoterol/budesonide (FBC) with sustained maintenance therapy EXCEL. In: American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego. 2005:[C33] [Poster: F68]. x-wiley/crsRef/3301301
34. GlaxoSmithKline SAM40040. A twenty-four week, randomised, double-dummy, double-blind, parallel group study to compare the rate of asthma exacerbations between SERETIDE DISKUS 50/250ìg 1 inhalation bd and formoterol/budesonide Breath-Actuated Dry Powder Inhaler (BADPI) 4.5/160ìg 2 inhalations bd in subjects with moderate to severe asthma. www.gsk-studyregister.com/en/trial-details/?id=SAM40040 (first received 1 November 2001). x-wiley/crsRef/3301302
35. Emeryk A, Klink R, McIver T, Dalvi P. A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma. Therapeutic Advances in Respiratory Disease 2016;10(4):324-37. x-wiley/crsRef/15978845
36. EUCTR-005928-16-FR. An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects with mild to moderate persistent, reversible asthma. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-005928-16-FR (first received 26 March 2007). x-wiley/crsRef/15978846
37. McIver T, Emeryk A, Klink R, Schwab B. Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma. In: European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam,. 2011:882s [P4822]. x-wiley/crsRef/15978847
38. EUCTR-002587-99-CZ. A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 µg plus formoterol 6 µg/actuation), 2 puffs b.i.d., versus beclomethasone dipropionate HFA (250 µg/actuation), 4 puffs b.i.d., versus Seretide® 500/50 (fluticasone 500 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., in patients with severe asthma. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-002587-99-CZ (first received 13 September 2007). x-wiley/crsRef/15978849
39. EUCTR-003449-17-IT. A study, 12 weeks, conducted in more centers, treatment with randomly assigned, double-blind, ''double-dummy'', in two parallel groups to compare the efficacy and safety of the combination of Foster NEXThaler, 2 inhalations bid, compared to Seretide Accuhaler, 1 inhalation, the derived parameters of small airways in patients with asthma. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-003449-17-IT (first received 31 May 2012). x-wiley/crsRef/15978851
40. NCT01570478. A study in patients with asthma (NELSON) [A 12-week, multicenter, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation), 2 inhalations b.i.d., versus Seretide® Accuhaler® (fluticasone 250 µg plus salmeterol 50 µg/actuation), 1 inhalation b.i.d., on small airway derived parameters in patients with asthma]. clinicaltrials.gov/show/NCT01570478 (first received 4 April 2012). x-wiley/crsRef/15978852
41. EUCTR-004833-70-BG. A phase III, randomized, parallel group, open study to compare the therapeutic efficacy and safety of SMB budesonide-salmeterol DPI capsule 150/25µg BID delivered by the Axahaler® versus Symbicort® Turbuhaler® 200/12µg BID over 12 weeks in moderate to severe persistent asthmatic patients. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-004833-70-BG (first received 19 January 2009). x-wiley/crsRef/15978854
42. Hsieh M-J, Lai R-S, Wu C-L, Lai C-L, Wang C-C, Peng D-W, et al. A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan. European Respiratory Journal 2013;42:873s [P4120]. x-wiley/crsRef/15978856
43. Hsieh MJ, Lin YC, Lai RS, Wu CL, Lai CL, Wang CC, et al. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients. Journal of the Formosan Medical Association 2017;12:1078-85. x-wiley/crsRef/15978857
44. Ambrose H, Lawrance R, Goldman M. Beta-adrenergic receptor gly16arg variation: effect on response to budesonide/formoterol or fluticasone propionate/salmeterol in asthma patients. Chest 2007;132(4):478a. x-wiley/crsRef/15978858
45. Ambrose HJ, Lawrance RM, Cresswell CJ, Goldman M, Meyers DA, Bleecker ER. Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response. Respiratory Research 2012;13:37. x-wiley/crsRef/15978859
46. AstraZeneca (SD-0390735). Comparison of the efficacy and safety of one inhalation of Symbicort®Turbuhaler® 160/4.5 μg bid plus as-needed with two inhalations of SeretideTM EvohalerTM 25/125 μg bid plus Terbutaline Turbuhaler® 0.4 mg as-needed, and one inhalation of Symbicort® Turbuhaler® 320/9 μg bid plus Terbutaline Turbuhaler® 0.4 mg as-needed. A 6-month, randomised, double-blind, double-dummy, parallel-group, active-controlled,multicentre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/_mshost2715844/content/content/resources/media/2958892/sd-039-0735.pdf (first recevied 30 April 2009). x-wiley/crsRef/3301304
47. Bleecker ER, Postma DS, Lawrance R, Meyers DA, Ambrose H, Goldman M. Effect of polymorphisms in the beta2-adrenergic receptor gene (ADRB2) on response to long-acting beta2-agonist (LABA) therapy. Journal Allergy and Clinical Immunology 2007;119(2):523. x-wiley/crsRef/15978860
48. Boonsawat W. Cost-effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine 2010;4(4):571-8. x-wiley/crsRef/15978861
49. Buhl R, Kuna P. Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? European Respiratory Journal 2007;30(Suppl 51):617s [P3620]. x-wiley/crsRef/15978862
50. Goldman M, Lawrance RM, Bleecker ER, Meyers DA, Ambrose HJ. Effect of polymorphisms in the ADRB2 3' Untranslated Region (3'UTR) on response to inhaled corticosteroid and long-acting beta2-adrenergic agonist (ICS/LABA) combination therapy. Journal of Allergy and Clinical Immunology 2009;123(2):S137. x-wiley/crsRef/15978863
51. Kuna P, Peters J, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. European Respiratory Journal 2006;28(Suppl 50):205s [P1228]. x-wiley/crsRef/3301307
52. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice 2007;61(5):725-36. x-wiley/crsRef/3301308
53. Kuna P. Treatment comparison of budesonide formoterol with salmeterol fluticasone propionate in adults aged >= 16 years with asthma: post hoc analysis of a randomized, double-blind study. Clinical Drug Investigation 2010;30(9):565-79. x-wiley/crsRef/3301309
54. Miller E, FitzGerald JM. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology/Journal Canadien de Pharmacologie Clinique 2008;15(2):e165-76. x-wiley/crsRef/15978864
55. O'Connor RD, Patrick DL, Parasuraman B, Martin P, Goldman M. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. Journal of Asthma 2010;47(2):217-23. x-wiley/crsRef/15978865
56. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. European Journal of Allergy and Clinical Immunology 2007;62(10):1189-98. x-wiley/crsRef/3301311
57. Tamminen K, Laine J, Soini E, Martikainen J, Kankaanranta H. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion 2008;24(12):3453-61. x-wiley/crsRef/3301312
58. FDA. Clinical review of Dulera (NDA 22-518). www.fda.gov/media/100092/download (accessed before 18 November 2020). x-wiley/crsRef/3301314
59. Maspero J, Cherrez I, Nolte H. Long-term safety and tolerability of two doses of mometasone furoate/formoterol (MF/F) combination, administered via a metered-dose inhaler, for the treatment of moderate-to-severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology 2009;123(2 Suppl 1):S159. x-wiley/crsRef/3301315
60. Maspero J, Cherrez I, Nolte H. Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial [Abstract]. In: European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna. 2009:[E274]. x-wiley/crsRef/3301316
61. Maspero J, Nolte H, Cherrez I. Long-term safety of medium- and high-dose mometasone furoate/formoterol combination in persistent asthmatics: analysis of adverse event incidence, plasma cortisol, and ocular changes [Abstract]. In: European Respiratory Society Annual Congress; 2010 Sep 18-22; Barcelona. 2010:[P1211]. x-wiley/crsRef/3301317
62. Maspero J, Nolte H, Ojeda IC. Long-term safety of medium- and high-doses mometasone furoate/formoterol combination in persistent asthmatics: analysis of adverse events incidence, plasma cortisol, and ocular changes [Abstract]. Journal of Allergy and Clinical Immunology 2010;125(2 Suppl 1):AB197. x-wiley/crsRef/3301318
63. Maspero JF, Cherrez I, Nolte H. Mometasone furoate and formoterol (MF/F) combination administered via a metered-dose inhaler (MDI) for the treatment of asthma: results from a 1-yr safety study. In: American Thoracic Society International Conference; 2009 May 15-20; San Diego. 2009:A2768 [Poster #J37]. x-wiley/crsRef/3301319
64. Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate formoterol combination for treatment of patients with persistent asthma. Journal of Asthma 2010;47(10):1106-15. x-wiley/crsRef/15978866
65. NCT00379288. Study of mometasone furoate/formoterol combination and fluticasone/salmeterol in persistent asthmatics previously treated with inhaled glucocorticosteroids (P04139) [A 1-Year safety study of medium and high doses of mometasone furoate/formoterol combination formulation and medium and high doses of fluticasone/salmeterol in persistent asthmatics previously treated with medium to high doses of inhaled glucocorticosteroids]. clinicaltrials.gov/show/nct00379288 (first received 21 September 2006). x-wiley/crsRef/15978867
66. Barnes N, Van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpina M, et al. Maintenance of lung function and asthma control with extrafine beclomethasone/formoterol. European Respiratory Journal 2011;38(55):140s [P833]. x-wiley/crsRef/15978869
67. Barnes N, van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpina M, et al. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination. Pulmonary Pharmacology and Therapeutics 2013;26(5):555-61. x-wiley/crsRef/15978870
68. EUCTR-003740-11-ES. A phase 4, multinational, multicentre, double blind, double dummy, randomized, parallel group, controlled clinical study of fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg pmdi with hfa-134a propellant (chf1535, Foster®) versus fluticasone 250 µg plus salmeterol 50 µg dpi (Seretide® Diskus®) as maintenance treatment in controlled asthmatic patients. - facto study [Estudio fase iv, multinacional, multicentrico, doble ciego, doble simulacion, randomizado, de grupos paralelos, controlado, sobre la combinacion de dosis fijas de dipropionato de beclometasona 100 µg mas fumarato de formoterol 6 µg pmdi con propelente hfa-134a (chf1535, foster®) versus fluticasona 250 µg mas salmeterol 50 µg ips (seretide® diskus®) como tratamiento de mantenimiento de pacientes asmaticos controlados]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-003740-11-ES (first received 23 January 2009). x-wiley/crsRef/15978871
69. EUCTR-003740-11-NL. A phase 4, multinational, multicentre, double blind, double dummy, randomized, parallel group, controlled clinical study of fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg pmdi with hfa-134a propellant (chf1535, Foster®) versus fluticasone 250 µg plus salmeterol 50 µg dpi (Seretide® Diskus®) as maintenance treatment in controlled asthmatic patients. - facto study. www.clinicaltrialsregister.eu/ctr-search/trial/2008-003740-11/results (first received 6 January 2017). x-wiley/crsRef/15978872
70. NCT00901368. FACTO study (Foster® As Complete Treatment Option) [A phase 4, multinational, multicentre, double blind, double dummy, randomized, parallel group, controlled clinical study of fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg pmdi with hfa-134a propellant (chf1535, foster®) versus fluticasone 250 µg plus salmeterol 50 µg dpi (seretide® diskus®) as maintenance treatment in controlled asthmatic patients]. clinicaltrials.gov/show/NCT00901368 (first received 13 May 2009). x-wiley/crsRef/15978873
71. NCT00394368. Efficacy and tolerability of beclomethasone dipropionate 100 µg + formoterol 6 µg pMDI VIA HFA-134a vs. fluticasone 125 µg + salmeterol 25 µg pMDI [DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) IN THE 12-WEEK TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA]. clinicaltrials.gov/show/NCT00394368 (first received 1 November 2006). x-wiley/crsRef/15978874
72. Paggiaro P, Papi A, Feschenko YI, Nicolini G, Fabbri LM. Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma. European Respiratory Journal 2006;28(Suppl 50):205s [P1227]. x-wiley/crsRef/3301322
73. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. European Journal of Allergy and Clinical Immunology 2007;62(10):1182-8. x-wiley/crsRef/3301323
74. NCT00497237. Clinical trial of the efficacy and safety of beclomethasone dipropionate plus formoterol vs fluticasone propionate plus salmeterol in the 6 months step down treatment of asthma [Prospective, randomised, open-label, multicentre, active drug controlled, parallel group design clinical trial of the efficacy and safety of beclomethasone dipropionate 400 mcg + formoterol 24 mcg pMDI Via HFA-134a (Foster™) vs. fluticasone propionate 500 mcg + salmeterol xinafoate 100 mcg DPI (Seretide Diskus®) in the 6 months stepdown treatment of adult patients with controlled asthma]. clinicaltrials.gov/show/NCT00497237 (first received 6 July 2007). x-wiley/crsRef/15978876
75. Paggiaro P, Nicolini G, Crimi N, Fabbri LM, Olivieri D, Rossi A, et al. Asthma control and lung function after step down from high dose ICS/LABA combination therapy. European Respiratory Journal 2011;38(55):722s [P3967]. x-wiley/crsRef/15978877
76. Papi A, Nicolini G, Crimi N, Fabbri L, Olivieri D, Rossi A, et al. Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. Respiratory Research 2012;13:54. x-wiley/crsRef/15978878
77. CTRI//05/002704. Comparison of Flutiform, fluticasone and Seretide in treatment of moderate to severe asthma in paediatric patients aged 5 to less than 12 years. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/05/002704 (first received 28 May 2012). x-wiley/crsRef/15978880
78. Ploszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial. Therapeutic Advances in Respiratory Disease 2018;12:1753466618777924. x-wiley/crsRef/15978881
79. Ploszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S. Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal 2014;44:P1167. x-wiley/crsRef/15978882
80. Jenkins C, Wilson J, Rutherford C, Perry AS, Whitehead PJ. Asthma management costs are lower with combination fluticasone/salmeterol (25/50 mcg BD) in a single inhaler than with budesonide (800 mcg BD) plus eformoterol (12 mcg BD) via separate inhalers. Respirology 2002;7(Suppl):A20 Abstract number (P23). x-wiley/crsRef/3301325
81. Martin AA, Whitehead PJ, McCarthy TP. Asthma costs with salmeterol/fluticasone combination 50/250mcg bd compared to budesonide 800mcg bd plus formoterol 12mcg bd [abstract]. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D034 Poster C43. x-wiley/crsRef/3301326
82. Ringdal N, Chovan L, Chuchalin AG, Whitehead PJ. Advair™/Seretide™ (250µg/50µg bid) shows exacerbation benefit over budesonide 800µg + formoterol 12µg in moderate-severe asthma [abstract]. American Journal of Respiratory and Critical Care Medicine 2001;163(Suppl 5):A866. x-wiley/crsRef/3301327
83. Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Whitehead PJ, et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 mug bd Diskus vs. formoterol (12 mug bd) and budesonide (800 mug bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respiratory Medicine 2002;96(11):851-61. x-wiley/crsRef/3301328
84. Ringdal N, Chuchalin AG, Chovan L, Whitehead PJ. A comparison of Advair™/Seretide™ (salmeterol 50 µg/fluticasone propionate 250 µg bid) with formoterol 12 µg + budesonide 800 µg bid in moderate-severe asthma. American Journal of Respiratory and Critical Care Medicine 2000;161(Suppl 3):A196. x-wiley/crsRef/3301329
85. Rodriguez JM, Sondhi Sl. Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain. European Respiratory Journal 2003;22 (Suppl 45):Abstract No: [2255]. x-wiley/crsRef/3301330
86. Sondhi S, Martin A. Economic evaluation of salmeterol/fluticasone propionate combination versus budesonide/formoterol in the UK. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:[B106] Poster E5. x-wiley/crsRef/3301331
87. SAM40010. A randomised, double blind, double-dummy, parallel-group, twelve week comparison of salmeterol/fluticasone propionate (FP) DISKUS/ACCUHALER 50/100mcg bd. with budesonide 200mcg bd. plus formoterol 4.5mcg bd. (both by breath-activated dry powder inhaler [BADPI]) in adult and adolescent asthmatics. www.gsk-studyregister.com/en/trial-details/?id=SAM40010 (first received 26 January 2000). x-wiley/crsRef/3301333
88. SAM40048. Randomised, double-blind, parallel group study on the efficacy and tolerability of the salmeterol 50 mcg/fluticasone 250 mcg combination Diskus compared to the formoterol 6mcg / budesonide 200mcg combination Turbohaler administered twice daily in patients with moderate bronchial asthma. GlaxoSmithKline Clinical Trial Register (first received 16 August 2001). x-wiley/crsRef/3301335
89. EUCTR-000512-25-IT. Double blind, double dummy, randomised, parallel group, monocentric clinical trial on the effects of chf 1535 mdi or seretide dpi on biological and functional markers of small airways in patients with asthma: a pilot study - nd. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-000512-25-IT (first received 20 April 2006). x-wiley/crsRef/15978884
90. Scichilone N, Battaglia S, Sorino C, Paglino G, Martino L, Paterno A, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010;65(7):897-902. x-wiley/crsRef/15978885
91. Kemppinen A, Gardener E, Thomas V, Raju P, Callan C, McLoughlin A, et al. Pragmatic trial stepping down Flutiform in patients maintained on high dose ICS. Journal of Thoracic Disease 2016;8(Suppl 5):AB039. x-wiley/crsRef/15978887
92. Usmani OS, Kemppinen A, Gardener E, Thomas V, Konduru PR, Callan C, et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. Journal of Allergy and Clinical Immunology 2017;5(5):1378-87.e5. x-wiley/crsRef/15978888
93. Woo SD, Ye YM, Lee Y, Lee SH, Shin YS, Park JH, et al. Efficacy and safety of a pressurized metered-dose inhaler in older asthmatics: comparison to a dry powder inhaler in a 12-week randomized trial. Allergy, Asthma and Immunology Research 2020;12(3):454-66. x-wiley/crsRef/15978890
94. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2008;370(9605):2118-25. x-wiley/crsRef/3301337
95. Dhillon S, Keating GM. Beclometasone dipropionate/formoterol in an HFA-propelled pressurised metered-dose inhaler. Drugs 2006;66(11):1475-83. x-wiley/crsRef/3301339
96. Hampel FC, Martin P, Mezzanotte WS. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. Journal of Asthma 2008;45(4):265-72. x-wiley/crsRef/3301341
97. Jung KS, Uh ST, Lee YC, Shim JJ, Park SK, Williams AE, et al. Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. Current Medical Research and Opinion 2008;24(12):3571-82. x-wiley/crsRef/3301343
98. Lee DKC, Currie GP, Cockburtn WJ, Lipworth BJ. Comparison of budesonide/formoterol versus fluticasone/salmeterol combination inhalers in moderate persistent asthma. In: American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:D094 Poster 613. x-wiley/crsRef/3301345
99. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003;21(13):951-89. x-wiley/crsRef/3301347
100. NCT02491970. Small airway function of fluticasone/formoterol (Flutiform®) and fluticasone/salmeterol (RECONFFIRM) [A single-blind, randomized, active-controlled, multi-center and phase IV study to evaluate the small airway parameters of fluticasone/formoterol (Flutiform®) compared to fluticasone/salmeterol in asthma patients]. clinicaltrials.gov/show/NCT02491970 (first received 8 July 2015). x-wiley/crsRef/15978892
101. Rani S, Rawal M, Kumar S, Lamba S. To compare efficacy and safety of fixed drug combination of salmeterol / fluticasone and budesonide / formoterol on the lung functions in childhood patients with moderate persistent asthma. Indian Journal of Public Health Research and Development 2016;7(4):203-7. x-wiley/crsRef/15978894
102. JPRN-UMIN000006572. Study on the effects of the budesonide/formoterol combination formulation in improving airway inflammation and airway resistance in patients with bronchial asthma. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000006572 (first received 18 October 2011). x-wiley/crsRef/15978896
103. NCT03387241. Efficacy of FLUTIFORM ® vs Seretide® in moderate to severe persistent asthma in subjects aged ≥12 years [A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to severe persistent, reversible asthma]. ClinicalTrials.gov/show/NCT03387241 (first received 2 January 2018). x-wiley/crsRef/15978898
104. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
105. Anderson GP. Current issues with beta(2)-adrenoceptor agonists - pharmacology and molecular and cellular mechanisms. Clinical Reviews in Allergy and Immunology 2006;31(2-3):119-30.
106. Arnold JMO, Oconnor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG. Effects of the beta-2-adrenoceptor antagonist ici-118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. British Journal of Clinical Pharmacology 1985;19(5):619-30.
107. Barnes PJ. Beta-adrenoceptors on smooth-muscle, nerves and inflammatory cells. Life Sciences 1993;52(26):2101-9.
108. Barnes PJ. Beta-adrenergic receptors and their regulation. American Journal of Respiratory and Critical Care Medicine 1995;152(3):838-60.
109. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. European Respiratory Journal 2002;19:182-91.
110. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994;49(8):771-4.
111. Bijl-Hofland ID, Cloosterman SG, Folgering HT, Van den Elshout FJ, Van Weel C, Van Schayck CP. Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine 2001;164(5):764-9.
112. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2-receptor stimulation by circulating epinephrine. New England Journal of Medicine 1983;309(23):1414-9.
113. Burgess CD, Windom HH, Pearce N, Marshall S, Beasley R, Siebers RWL, et al. Lack of evidence for beta-2 receptor selectivity - a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma. American Review of Respiratory Disease 1991;143(2):444-6.
114. Burggraaf J, Westendorp RGJ, in't Veen J, Schoemaker RC, Sterk PJ, Cohen AF, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001;56(7):567-9.
115. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No: CD006363. [DOI: 10.1002/14651858.CD006363.pub2]
116. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No: CD006923. [DOI: 10.1002/14651858.CD006923.pub2]
117. Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No: CD007695. [DOI: 10.1002/14651858.CD007695.pub3]
118. Cates CJ, Schmidt S, Ferrer M, Sayer B, Waterson S. Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No: CD006922. [DOI: 10.1002/14651858.CD006922.pub4]
119. Cochrane Airways Trials Register. airways.cochrane.org/trials-register (accessed 7 May 2019).
120. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342(8875):833-7.
121. Collins JM, McDevitt DG, Shanks RG, Swanton JG. Cardio-toxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1969;36(1):35-45.
122. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83 - case-control study. Lancet 1989;1(8644):917-22.
123. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No: CD005533. [DOI: 10.1002/14651858.CD005533.pub2]
124. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2011, Issue 5. Art. No: CD003137. [DOI: 10.1002/14651858.CD003137.pub4]
125. Giembycz MA, Newton R. Beyond the dogma: novel ß2-adrenoceptor signalling in the airways. European Respiratory Journal 2006;27(6):1286-306.
126. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7 - a further case-control study. Thorax 1991;46(2):105-11.
127. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000;55(8):650-6.
128. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2-adrenoceptors in the human-heart. Circulation Research 1989;65(3):546-53.
129. Hanania NA, Sharfkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy - measurement and clinical significance. American Journal of Respiratory and Critical Care Medicine 2002;165(10):1353-8.
130. Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, Sharafkhaneh A, et al. The role of intrinsic efficacy in determining response to beta(2)-agonist in acute severe asthma. Respiratory Medicine 2007;101(5):1007-14.
131. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to beta-agonists during acute bronchoconstriction. European Respiratory Journal 1999;14(2):283-7.
132. Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clinical Reviews in Allergy and Immunology 2006;31(2-3):231-46.
133. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clinical Reviews in Allergy and Immunology 2006;31(2-3):181-96.
134. Harvey JE, Tattersfield AE. Airway response to salbutamol - effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982;37(4):280-7.
135. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
136. Higgins JPT, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors(s). Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. 2019:143-76.
137. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 [updated September 2020]. Cochrane, 2020. Available from training.cochrane.org/handbook.
138. Clinical safety data management: definitions and standards for expedited reporting. www.ema.europa.eu/en/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting (accessed before 19 November 2020).
139. Janjua S, Schmidt S, Ferrer M, Cates CJ. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No: CD006924. [DOI: 10.1002/14651858.CD006924.pub4]
140. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. European Respiratory Journal 2001;17(3):368-73.
141. Lasserson TJ, Cates CJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD004106. [DOI: 10.1002/14651858.CD004106.pub3]
142. Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. British Journal of Clinical Pharmacology 2003;56(5):494-500.
143. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, et al. Chapter 4. Searching for studies. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.1 [updated September 2020]. Cochrane, 2020.
144. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high-dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989;140(3):586-92.
145. Lipworth BJ, McDevitt DG. Inhaled beta-2-adrenoceptor agonists in asthma - help or hindrance. British Journal of Clinical Pharmacology 1992;33(2):129-38.
146. Lipworth BJ. Airway sub-sensitivity with long-acting beta 2-agonists: is there cause for concern? Drug Safety 1997;16(5):295-308.
147. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000;117(1):156-62.
148. Lötvall J. Pharmacological similarities and differences between beta2-agonists. Respiratory Medicine 2001;95(Suppl B):S7-11. [DOI: 10.1053/rmed.2001.1139]
149. Marshall IJ, Noel-Storr AH, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying randomized controlled trials: an evaluation and practitioner’s guide. Research Synthesis Methods 2018;9(4):602-14.
150. McDevitt DG, Shanks RG, Swanton JG. Further observations on cardiotoxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1974;50(3):335-44.
151. McDonald S, Noel-Storr AH, Thomas J. Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. In: Global Evidence Summit; 2017 September 13-16; Cape Town, South Africa. 2017.
152. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine 1998;158(3):924-30.
153. Morrison KJ, Gao Y, Vanhoutte PM. Beta-adrenoceptors and the epithelial layer in airways. Life Sciences 1993;52(26):2123-30.
154. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to bronchodilator action of albuterol produced by chronic administration. American Review of Respiratory Disease 1977;116(5):871-8.
155. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No: CD005307. [DOI: 10.1002/14651858.CD005307]
156. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No: CD005535. [DOI: 10.1002/14651858.CD005535.pub2]
157. Noel-Storr AH, Project Transform Team. Cochrane Crowd: new ways of working together to produce health evidence. In: Evidence Live; 2018 June 18-20; Oxford, UK.
158. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan - a web and mobile app for systematic reviews. Systematic Reviews 2016;5:210. [DOI: 10.1186/s13643-016-0384-4.]
159. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine 1999;160(1):244-9.
160. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990;45(3):170-5.
161. Pearce N. Adverse Reactions: The Fenoterol Story. 1st edition. Auckland: Auckland University Press, 2007. [9781869403744]
162. Peters SP, Bleecker ER, Canonica GW, Park YB, Ramirez R, Hollis S, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine 2016;375(9):850-60. x-wiley/crsRef/12109244
163. The Nordic Cochrane Centre: The Cochrane Collaboration Review Manager (RevMan) Version 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2008.
164. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904-12.
165. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial-asthma. Lancet 1990;336(8728):1391-6.
166. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
167. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. British Medical Journal 1968;1(5588):335-9.
168. Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett MS, Prazma CM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. New England Journal of Medicine 2016;374(19):1822-30. x-wiley/crsRef/9539219 [DOI: 10.1056/NEJMoa1511049]
169. Stempel DA, Szefler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. New England Journal of Medicine 2016;375(9):840-9. x-wiley/crsRef/9539389 [DOI: 10.1056/NEJMoa1606356]
170. Thomas J, Noel-Storr AH, Marshall I, Wallace B, McDonald S, Mavergames C, et al. Living systematic review network. Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology 2017;91:31-7.
171. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta(2) agonists. Thorax 2001;56(7):529-35.
172. vanNoord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996;9(8):1684-8.
173. Walters EH, Walters JAE, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No: CD003901. [DOI: 10.1002/14651858.CD003901]
174. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for stable chronic asthma. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No: CD001385. [DOI: 10.1002/14651858.CD001385.pub2]
175. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics - development of subsensitivity with long-term administration. Journal of Allergy and Clinical Immunology 1982;70(6):417-22.
176. Weinstein CLJ, Ryan N, Shekar T, Gates D, Lane SJ, Agache I, et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology 2019;143(4):1395-402. x-wiley/crsRef/12109263 [DOI: 10.1016/j.jaci.2018.10.065]
177. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma. Lancet 1981;1(8232):1235-7.
178. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990;336(8728):1396-9.
179. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta(2)-agonist. American Journal of Respiratory and Critical Care Medicine 1996;154(6):1603-7.
180. Cates CJ, Lasserson T. Regular fixed-dose treatment with formoterol and inhaled corticosteroids versus regular treatment with salmeterol and inhaled corticosteroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD007694. [DOI: 10.1002/14651858.CD007694]
181. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD007694. [DOI: 10.1002/14651858.CD007694.pub2]